 | • レポートコード：TPM-C02171 • 出版社/出版日：Transparency Market Research / 2018年10月31日 • レポート形態：英文、PDF、106ページ • 納品方法：Eメール • 産業分類：Healthcare |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Global Site License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、遺伝子治療の世界市場について調べ、遺伝子治療の世界規模、市場動向、市場環境、製品別（Yescarta、Kymriah、Luxturna、Strimvelis、Gendicine）分析、用途別（眼科、がん、アデノシンデアミナーゼ欠損重症複合免疫不全（ADA-SCID））分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、関連企業情報などをまとめた調査レポートです。 ・序文・調査範囲・調査手法 ・エグゼクティブサマリー ・遺伝子治療の世界市場動向 ・遺伝子治療の世界市場環境 ・遺伝子治療の世界市場規模 ・遺伝子治療の世界市場規模：製品別（Yescarta、Kymriah、Luxturna、Strimvelis、Gendicine） ・遺伝子治療の世界市場規模：用途別（眼科、がん、アデノシンデアミナーゼ欠損重症複合免疫不全（ADA-SCID）） ・遺伝子治療の世界市場：地域別市場規模・分析 ・遺伝子治療の北米市場規模・予測 ・遺伝子治療のアメリカ市場規模・予測 ・遺伝子治療のヨーロッパ市場規模・予測 ・遺伝子治療のアジア市場規模・予測 ・競争状況・関連企業情報 |
Gene Therapy Market – Overview
This report studies the current as well as future prospects of the global gene therapy market. Stakeholders of this report include companies and intermediaries engaged in the manufacture, commercialization, and provision of gene therapy products and new entrants planning to enter the market. This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments considered in the scope of the study. This section also provides the overall information and data analysis of the global gene therapy market regarding leading segments based on product, application, and region.
The global gene therapy market has been segmented based on product, application, and region. In terms of product, the global market has been classified into Yescarta, Kymriah, Luxturna, Strimvelis, and Gendicine. In terms of application, the global market has been divided into ophthalmology, oncology, and adenosine deaminase?deficient severe combined immunodeficiency (ADA-SCID).
The market revenue for each product was estimated using bottom-up approach. The revenue generated by each product and application has been calculated considering marketing approvals of the products, sales, number of patients treated, cost of products, and pattern in different regions. The bottom-up approach for determining the country market size was studied using various market indicators obtained from secondary sources, which include different products and their applications and their cost variations in major country/region, prevalence and incidence in major countries for eligible patients with relapsed or refractory large B-cell lymphoma including diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), acute lymphoblastic leukemia (ALL), acute lymphoblastic leukemia (ALL) and head and neck cancer. Revenues of all publicly listed market players were obtained through secondary sources and analyzed for gene therapy specific revenues by narrowing down to revenue percentage for product segment through extensive secondary analysis of annual reports, investor presentations, press releases, primary interviews, and others. Data triangulation is based on secondary research (top-down and bottom-up approaches) and primary research. Moreover, historical year-on-year growth has been taken into consideration while estimating the market size. The market size and forecast in terms of US$ Mn for each segment has been provided for the period from 2017 to 2026. The report also provides the compound annual growth rate (CAGR %) for each segment for the forecast period from 2018 to 2026, considering 2017 as the base year.
The market overview section of the report explores market dynamics such as drivers, restraints, opportunities, and key trends that have a strong impact on the gene therapy market and could influence it in the near future. Market attractiveness analysis has been provided to explain the intensity of competition across different regions. The competitive scenario among different players is evaluated through market share analysis in the competitive landscape section of the report. These factors are likely to help market players take strategic decisions to strengthen their positions and expand their shares in the global gene therapy market.
In terms of region, the global gene therapy market has been segmented into the U.S., Europe, and rest of world. The market size and forecast for each of these regions has been provided for the period from 2017 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year. A detailed qualitative analysis of factors responsible for driving and restraining the market and future opportunities has been provided in the overview section. This section of the report also provides the market attractiveness analysis and market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario in the global gene therapy market.
Major players operating in the global gene therapy market include Gilead Sciences, Inc., Novartis AG, Sibiono GeneTech Co. Ltd., Spark Therapeutics, Inc., CELGENE CORPORATION, and Orchard Therapeutics Limited.
The global gene therapy market has been segmented as follows:
Global Gene Therapy Market, by Product
Yescarta
Kymriah
Luxturna
Strimvelis
Gendicine
Global Gene Therapy Market, by Application
Ophthalmology
Oncology
Adenosine Deaminase?Deficient Severe Combined Immunodeficiency (ADA-SCID)
Global Gene Therapy Market, by Region
U.S.
Europe
Rest of World
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
2. Assumptions and Research Methodology
3. Executive Summary : Global Gene Therapy Market
4. Market Overview
4.1. Introduction
4.1.1. Gene Therapy Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Gene Therapy Market Analysis and Forecasts, 2017–2026
5. Market Outlook
5.1.Clinical Trial Pipeline Analysis
6. Global Gene Therapy Market Analysis and Forecasts, by Product
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Global Gene Therapy Market Value Forecast, by Product, 2017–2026
6.3.1. Yescarta
6.3.2. Kymriah
6.3.3. Luxturna
6.3.4. Strimvelis
6.3.5. Gendicine
6.4. Market Attractiveness, by Product
7. Global Gene Therapy Market Analysis and Forecasts, by Application
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Global Gene Therapy Market Value Forecast, by Application, 2017–2026
7.3.1. Ophthalmology
7.3.2. Oncology
7.3.3. Adenosine Deaminase?Deficient Severe Combined Immunodeficiency (ADA-SCID)
7.4. Global Gene Therapy Market Attractiveness, by Application
8. U.S. Gene Therapy Market Analysis and Forecast
8.1. Introduction
8.2. U.S. Gene Therapy Market Value Forecast, by Product, 2017–2026
8.2.1. Yescarta
8.2.2. Kymriah
8.2.3. Luxturna
8.2.4. Strimvelis
8.2.5. Gendicine
8.3. U.S. Gene Therapy Market Value Forecast, by Application, 2017–2026
7.3.1. Ophthalmology
7.3.2. Oncology
7.3.3. Adenosine Deaminase?Deficient Severe Combined Immunodeficiency (ADA-SCID)
8.4. U.S. Gene Therapy Market Attractiveness Analysis
8.4.1. By Product
8.4.2. By Application
9. Europe Gene Therapy Market Analysis and Forecast
9.1. Introduction
9.2. Europe Gene Therapy Market Value Forecast, by Product, 2017–2026
9.2.1. Yescarta
9.2.2. Kymriah
9.2.3. Luxturna
9.2.4. Strimvelis
9.2.5. Gendicine
9.3. Europe Gene Therapy Market Value Forecast, by Application, 2017–2026
9.3.1. Ophthalmology
9.3.2. Oncology
9.3.3. Adenosine Deaminase?Deficient Severe Combined Immunodeficiency (ADA-SCID)
9.4. Europe Gene Therapy Market Attractiveness Analysis
9.4.1. By Product
9.4.2. By Application
10. Rest of World Gene Therapy Market Analysis and Forecast
10.1. Introduction
10.2. Rest of World Gene Therapy Market Value Forecast, by Product, 2017–2026
10.2.1. Yescarta
10.2.2. Kymriah
10.2.3. Luxturna
10.2.4. Strimvelis
10.2.5. Gendicine
10.3. Rest of World Gene Therapy Market Value Forecast, by Application, 2017–2026
10.3.1. Ophthalmology
10.3.2. Oncology
10.3.3. Adenosine Deaminase?Deficient Severe Combined Immunodeficiency (ADA-SCID)
10.4. Rest of World Gene Therapy Market Attractiveness Analysis
10.4.1. By Product
10.4.2. By Application
11. Competition Landscape
11.1.Market Player – Competition Matrix (By Tier and Size of companies)
11.2.Market Share Analysis, by Company (2017)
11.3. Company Profiles
11.3.1. Novartis AG
Company Overview (HQ, Business Segments, Employee Strength)
Product Portfolio
SWOT Analysis
Strategic Overview
Financial Overview
11.3.2. Orchard Therapeutics Limited.
Company Overview (HQ, Business Segments, Employee Strength)
Product Portfolio
SWOT Analysis
Strategic Overview
11.3.3. CELGENE CORPORATION
Company Overview (HQ, Business Segments, Employee Strength)
Product Portfolio
SWOT Analysis
Financial Overview
Strategic Overview
11.3.4. Spark Therapeutics, Inc.
Company Overview (HQ, Business Segments, Employee Strength)
Product Portfolio
SWOT Analysis
Financial Overview
Strategic Overview
11.3.5. Gilead Sciences, Inc.
Company Overview (HQ, Business Segments, Employee Strength)
Product Portfolio
SWOT Analysis
Financial Overview
Strategic Overview
11.3.6. Sibiono GeneTech Co. Ltd.
Company Overview (HQ, Business Segments, Employee Strength)
Product Portfolio
SWOT Analysis
Strategic Overview
Table 01: Pipeline Analysis: Gene therapy Candidates (1/8)
Table 02: Pipeline Analysis: Gene therapy Candidates (2/8)
Table 03: Pipeline Analysis: Gene therapy Candidates (3/8)
Table 04: Pipeline Analysis: Gene therapy Candidates (4/8)
Table 05: Pipeline Analysis: Gene therapy Candidates (5/8)
Table 06: Pipeline Analysis: Gene therapy Candidates (6/8)
Table 07: Pipeline Analysis: Gene therapy Candidates (7/8)
Table 08: Pipeline Analysis: Gene therapy Candidates (8/8)
Table 09: Global Gene Therapy Market Size (US$ Mn) Forecast, by Type, 2017–2026
Table 10: Global Gene Therapy Market Size (US$ Mn) Forecast, by Application, 2017–2026
Table 11: U.S. Gene Therapy Market Size (U.S.$ Mn) Forecast, by Product, 2017–2026
Table 12: U.S. Gene Therapy Market Size (U.S.$ Mn) Forecast, by Application, 2017–2026
Table 13: Europe Gene Therapy Market Size (US$ Mn) Forecast, by Product, 2017–2026
Table 14: Europe Gene Therapy Market Size (US$ Mn) Forecast, by Application, 2017–2026
Table 15: Rest of the World Gene Therapy Market Size (US$ Mn) Forecast, by Product, 2017–2026
Table 16: Rest of the World Gene Therapy Market Size (US$ Mn) Forecast, by Application, 2017–2026